← All diseases

Eye and hearing diseases

Achromatopsia (complete color blindness)

An inherited disease in which the retinal cells responsible for color and daylight vision do not work. Colors are seen poorly or not at all. It comes with sensitivity to light and low vision.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

This page is translated from the Turkish original.

This disease is followed through the “Eye and hearing diseases” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

The retina has two kinds of light cells: rods and cones. Cones allow vision in daylight, color vision and sharp vision. In achromatopsia, the cones do not work at all or work very little. The disease usually does not progress; symptoms stay similar throughout life.

Which symptoms can occur?

Symptoms begin in the first weeks after birth. The first thing noticed is usually shaking of the eyes.

  • Involuntary shaking of the eyes, called nystagmus
  • Extreme sensitivity to light and glare
  • Clearly reduced vision, blurred vision
  • Seeing no colors or very few colors
  • A small blind spot in the middle of the field of vision
  • Refractive errors such as hyperopia or myopia

How is it diagnosed?

The eye doctor tests sharpness of vision, color vision and the field of vision. An ERG test shows whether the cones respond to light. Imaging methods such as OCT show the structure of the retina. A genetic test supports the diagnosis.

Treatment and care

There is no approved treatment at the moment. Care aims to ease the symptoms. Glasses with special filters, dark glasses or red-tinted lenses can reduce light sensitivity. Magnifiers and other low vision aids make reading easier. At school, it helps for the child to sit in the front row and away from the window. Eye checks are recommended every 6 to 12 months in childhood and every 2 to 3 years in adulthood. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

It is inherited recessively. For a carrier couple, the chance of an affected child in each pregnancy is 1 in 4. Carrier mothers and fathers usually have no symptoms. This chance can be higher when parents are related by blood. Girls and boys are affected equally often. Genetic counselling is recommended.

Source: MedlinePlus Genetics: Achromatopsia · NORD: Achromatopsia · Orphanet: Achromatopsia (ORPHA:49382)

Key facts

How common is it?
Prevalence: 1-9 per 100 000 (Worldwide)
How is it inherited?
Autosomal recessive
When does it usually start?
Infancy, Newborn period
Gene(s) involved
CNGA3, CNGB3, GNAT2, PDE6H, PDE6C, ATF6

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

We could not find a patient association specific to this disease.

For all rare diseases: Nadir Hastalıklar Federasyonu

Guides related to this disease

  • Rare disease at school · Telling the school, medicines and emergency plan, inclusion and BEP, support education room, absences, LGS/YKS arrangements, peer bullying.

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about Achromatopsia

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

Questions you can ask your doctor

  • Could this trial be suitable for us?
  • If we take part, how would current treatment and check-ups be affected?
  • Where does the trial take place, and how are travel and accommodation handled?
  • What happens if we want to leave the trial?

ClinicalTrials.gov lists 1 active interventional study for this disease. None is recruiting right now; none has a site in Türkiye. Last checked: October 7, 2026.

Selected records (studies with a site in Türkiye first):

See all studies on ClinicalTrials.gov · Joining clinical trials

Eye and hearing diseases: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:49382

No separate ICD-11 code; WHO classifies this disease under: 9B70

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.